Controller medications for asthma dispensed in 12 months prior to mepolizumab
| Medication use | |||
| No dispensings | One or more dispensings | Two or more dispensings | |
| Severe asthma* | 45% (1561) | 55% (1935) | 14% (500) |
| ICS alone | |||
| Low-dose ICS | 87% (3034) | 13% (462) | 5% (173) |
| Medium-high ICS* | 78% (2712) | 22% (784) | 7% (243) |
| High-dose inhaled corticosteroids (ICS)* | 87% (3053) | 13% (443) | 5% (161) |
| ICS/LABA | |||
| Low-dose ICS/LABA | 66% (2292) | 34% (1,204) | 14% (490) |
| Medium-high dose ICS/LABA* | 84% (2954) | 16% (542) | 6% (211) |
| ICS/LABA (any dose) | 51% (1800) | 49% (1696) | 20% (714) |
| ICS/LTRA | |||
| Low-dose ICS/LTRA | 92% (3225) | 8% (271) | 2% (76) |
| High-dose ICS/LTRA* | 93% (3234) | 7% (262) | 2% (67) |
| Biologics | |||
| Omalizumab* | 88% (3079) | 12% (303) | 9% (303) |
| Reslizumab* | 100% (3491) | 0% (3) | 0% (3) |
| Benralizumab* | 99% (3478) | 1% (7) | 0% (7) |
| Dupilumab* | 100% (3493) | 0% (2) | 0% (2) |
| Other controller medications | |||
| Oral corticosteroids (days supply ≥28 days)* | 72% (2525) | 28% (971) | 13% (470) |
| Tiotropium | 77% (2680) | 23% (816) | 6% (218) |
N=3496.
*Medications included in definition of severe asthma.
ICS, inhaled corticosteroids; LABA, long-acting beta agonists; LTRA, leukotriene receptor antagonists.